GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Other Current Receivables

RemeGen Co (HKSE:09995) Other Current Receivables : HK$256 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Other Current Receivables?

RemeGen Co's Other Current Receivables for the quarter that ended in Dec. 2024 was HK$256 Mil.

RemeGen Co's quarterly Other Current Receivables increased from Dec. 2023 (HK$166.22 Mil) to Jun. 2024 (HK$285.69 Mil) but then stayed the same from Jun. 2024 (HK$285.69 Mil) to Dec. 2024 (HK$256.40 Mil).

RemeGen Co's annual Other Current Receivables increased from Dec. 2022 (HK$108.43 Mil) to Dec. 2023 (HK$166.22 Mil) and increased from Dec. 2023 (HK$166.22 Mil) to Dec. 2024 (HK$256.40 Mil).


RemeGen Co Other Current Receivables Historical Data

The historical data trend for RemeGen Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Other Current Receivables Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Receivables
Get a 7-Day Free Trial 4.96 14.94 108.43 166.22 256.40

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.43 115.67 166.22 285.69 256.40

RemeGen Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


RemeGen Co Other Current Receivables Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Executives
I-nova Limited 2101 Beneficial owner
Yantai Rongda Venture Capital Center (limited Partnership) 2103 Interests held jointly with another person
Yang Minhua 2103 Interests held jointly with another person
Xiong Xiaobin 2103 Interests held jointly with another person
Wen Qingkai 2103 Interests held jointly with another person
Deng Yong 2103 Interests held jointly with another person
Fang Jianmin 2103 Interests held jointly with another person
Lin Jian 2103 Interests held jointly with another person
Rongchang Holding Group Ltd. 2103 Interests held jointly with another person
Wang Liqiang 2103 Interests held jointly with another person
Wang Weidong 2201 Interest of corporation controlled by you
Wang Xudong 2103 Interests held jointly with another person
Wei Jianliang 2103 Interests held jointly with another person
Morgan Stanley 2201 Interest of corporation controlled by you
Allianz Se 2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines